BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS
· Phase II monotherapy study of bemcentinib in high-risk MDS & AML · Will enrol up to 43 patients at leading MDS centres across Europe · Investigator sponsored trial led by Prof. Uwe PlatzbeckerBergen, Norway, Jan 4th 2019 - BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who have failed first-line treatment with hypomethylating agents. The trial may also enrol a proportion of